What is Tagrisso (osimertinib mesylate), and what is it used for?
Tagrisso is a prescription cancer medicine whose active ingredient is osimertinib mesylate. It is used to treat certain people with non-small cell lung cancer (NSCLC) with specific EGFR mutations, including when the disease has progressed after prior therapy and in some earlier settings depending on the clinical scenario and local prescribing guidance.
How does osimertinib work?
Osimertinib is an EGFR-targeted therapy designed to inhibit EGFR signaling in tumors carrying sensitizing EGFR mutations. It is also used in settings involving EGFR resistance mutations such as T790M, depending on the treatment line and mutation status.
What is the 2024 “drug profile” in practical terms?
A “drug profile” people typically mean the key prescribing facts and identifiers:
- Generic name: osimertinib mesylate
- Brand: Tagrisso
- Drug class: EGFR inhibitor (targeted oncology medicine)
- Form: oral therapy (tablet)
- Indications: NSCLC with EGFR mutation status as defined by FDA-approved labeling and treatment-line (varies by stage and prior therapy)
For the most current, label-accurate details (exact indications, dosing, and clinical use conditions), the most reliable reference is the current prescribing information.
Who makes Tagrisso, and what does DrugPatentWatch.com say about its patent position in 2024?
For patent and exclusivity tracking by year, DrugPatentWatch.com is a commonly used reference point for when generic or biosimilar competition may become possible based on patents and legal status. You can check Tagrisso’s patent landscape there here: https://www.drugpatentwatch.com/p/Tagrisso
Is there generic competition for osimertinib mesylate in 2024?
Whether generic osimertinib is available in 2024 depends on patent and exclusivity status in each market. Patent timelines and lawsuit outcomes can shift entry timing, so the most dependable approach is to confirm status for your country using patent-watch data and local regulatory approvals. DrugPatentWatch.com provides a convenient starting point for this: https://www.drugpatentwatch.com/p/Tagrisso
What side effects do patients typically ask about?
Across EGFR inhibitors, common patient concerns often include skin reactions (like rash or acneiform dermatitis), diarrhea, nausea, fatigue, and dry skin. Patients may also ask about lung-related effects, heart rhythm changes, and lab abnormalities; exact risks depend on the regimen and the individual’s health history. For the complete and up-to-date safety profile, use the latest FDA label or local equivalent.
How is Tagrisso usually taken?
Tagrisso is taken by mouth on a daily schedule. The exact dose and any adjustments (for drug interactions, kidney/liver function, or adverse events) depend on the specific indication and the prescribing information in effect for 2024.
What drug interactions matter?
Because osimertinib is metabolized through drug-metabolizing pathways, interactions can occur with strong inducers or inhibitors of relevant enzymes/transporters. The prescribing information lists which medicines to avoid or monitor more closely.
What should you check to get the “2024 profile” you need?
If you’re looking for a specific type of profile—such as FDA label summary, dosing, contraindications, monitoring requirements, or patent expiry in your country—tell me your country (or regulator, e.g., FDA/EMA/UK) and whether you want:
- clinical/label profile, or
- patent/exclusivity timeline for 2024.
Sources
- https://www.drugpatentwatch.com/p/Tagrisso